S. Korean drug firms ink major COVID-19 vaccine, treatment manufacturing deals

Yonhap News Agency | Nov 18, 2020 at 2:02 AM
  • A number of major South Korean pharmaceutical companies have recently signed a series of deals to manufacture vaccines and treatment drugs for the novel coronavirus, industry watchers said Wednesday.
  • Under the CMO agreement, Samsung Biologics will provide Eli Lilly’s investigational neutralizing antibody for the treatment of COVID-19 patients.
  • The U.S. Food and Drug Administration granted emergency use authorization for the investigational therapy.